Articles

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Hematology, Dept of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Dept of Translational & Precision Medicine, Sapienza University & GIMEMA Data Center, Rome, Italy;
Dept of Translational & Precision Medicine, Sapienza University & GIMEMA Data Center, Rome, Italy;
GIMEMA Data Center, Fondazione GIMEMA Franco Mandelli Onlus, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Department of Medicine, Hematology & Bone Marrow Transplantation Unit, University of Perugia, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Department of Medicine, Hematology & Bone Marrow Transplantation Unit, University of Perugia, Italy;
Div of Hematology & Bone Marrow Transplantation,Ospedali Riuniti Villa Sofia-Cervello, Palermo,Italy;
Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome;
Dept. of General Surgery and Medical-Surgical Specialties, University of Catania, Italy;
Hematology Division, S. Eugenio Hospital, Rome, Italy;
Seragnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy;
Clinica di Ematologia e Unita' di terapie Cellulari Carlo Melzi, Udine, Italy;
Division of Hematology, Niguarda Hospital, Milano, Italy;
Dept of Oncology, Division of Hematology, Presidio Molinette, Torino, Italy;
UOC Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Italy;
Department of Hematology, Ospedale S. Croce, Cuneo, Italy;
Department of Hematology, ASST Spedali Civili, Brescia, Italy;
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
GIMEMA Data Center, Fondazione GIMEMA Franco Mandelli Onlus, Rome, Italy;
GIMEMA Data Center, Fondazione GIMEMA Franco Mandelli Onlus, Rome, Italy;
Dept. of Medicine, Hematology & Bone Marrow Transplantation Unit, University of Perugia, Italy;
Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy;
Department of Molecular Medicine, Sapienza University, Rome, Italy;
Hematology Unit, Ospedale dell'Angelo and Ospedale Ss Giovanni e Paolo, Mestre Venezia, Italy
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy;
Haematologica Early view May 28, 2020 https://doi.org/10.3324/haematol.2020.247973